JP2008508253A - Ｃｃｒ２を介した疾患又は障害の治療法 - Google Patents

Ｃｃｒ２を介した疾患又は障害の治療法 Download PDF

Info

Publication number
JP2008508253A
JP2008508253A JP2007523167A JP2007523167A JP2008508253A JP 2008508253 A JP2008508253 A JP 2008508253A JP 2007523167 A JP2007523167 A JP 2007523167A JP 2007523167 A JP2007523167 A JP 2007523167A JP 2008508253 A JP2008508253 A JP 2008508253A
Authority
JP
Japan
Prior art keywords
ccr2
therapeutic
patient
mice
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007523167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508253A5 (cg-RX-API-DMAC10.html
Inventor
コーネリアス，ピーター
ポール グラデュー，ロナルド
セバスチャン ガロファロ，ロバート
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2008508253A publication Critical patent/JP2008508253A/ja
Publication of JP2008508253A5 publication Critical patent/JP2008508253A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2007523167A 2004-07-30 2005-07-18 Ｃｃｒ２を介した疾患又は障害の治療法 Withdrawn JP2008508253A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59268304P 2004-07-30 2004-07-30
PCT/IB2005/002162 WO2006013427A2 (en) 2004-07-30 2005-07-18 Treatment of ccr2 mediated diseases or disorders

Publications (2)

Publication Number Publication Date
JP2008508253A true JP2008508253A (ja) 2008-03-21
JP2008508253A5 JP2008508253A5 (cg-RX-API-DMAC10.html) 2008-08-14

Family

ID=35207829

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007523167A Withdrawn JP2008508253A (ja) 2004-07-30 2005-07-18 Ｃｃｒ２を介した疾患又は障害の治療法

Country Status (14)

Country Link
US (1) US20090196823A1 (cg-RX-API-DMAC10.html)
EP (1) EP1778285A2 (cg-RX-API-DMAC10.html)
JP (1) JP2008508253A (cg-RX-API-DMAC10.html)
KR (1) KR20080044360A (cg-RX-API-DMAC10.html)
CN (1) CN101005855A (cg-RX-API-DMAC10.html)
AU (1) AU2005268545A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0513953A (cg-RX-API-DMAC10.html)
CA (1) CA2575612A1 (cg-RX-API-DMAC10.html)
IL (1) IL180675A0 (cg-RX-API-DMAC10.html)
MX (1) MX2007001204A (cg-RX-API-DMAC10.html)
NO (1) NO20070996L (cg-RX-API-DMAC10.html)
RU (1) RU2007103332A (cg-RX-API-DMAC10.html)
WO (1) WO2006013427A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200700823B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520773A (ja) * 2011-06-27 2014-08-25 ウニヴェルシテ ピエール エ マリー キュリー（パリ ６） Ｃｃｒ２アンタゴニストペプチド

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
CN102239180B (zh) * 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
WO2022235440A1 (en) * 2021-04-21 2022-11-10 The United States Government As Represented By The Department Of Veterans Affairs Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
FR2792837B1 (fr) * 1999-04-29 2001-07-13 Centre Nat Rech Scient Medicaments utiles pour le traitement des troubles de la regulation de la masse adipeuse et des maladies associees aux troubles de la production de leptine
US20050245537A1 (en) * 2002-04-24 2005-11-03 Noboru Tsuchimori Use of compounds having ccr antagonism
US20060183731A1 (en) * 2003-07-15 2006-08-17 Min Ge 7 and 8 membered heterocyclic cyclopentyl benzylamide modulators of chemokine receptor activity
CA2550596C (en) * 2003-12-18 2011-03-15 Incyte Corporation 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520773A (ja) * 2011-06-27 2014-08-25 ウニヴェルシテ ピエール エ マリー キュリー（パリ ６） Ｃｃｒ２アンタゴニストペプチド

Also Published As

Publication number Publication date
BRPI0513953A (pt) 2008-05-20
RU2007103332A (ru) 2008-08-10
US20090196823A1 (en) 2009-08-06
EP1778285A2 (en) 2007-05-02
ZA200700823B (en) 2008-10-29
CN101005855A (zh) 2007-07-25
MX2007001204A (es) 2007-03-23
WO2006013427A3 (en) 2006-06-08
CA2575612A1 (en) 2006-02-09
NO20070996L (no) 2007-04-23
AU2005268545A1 (en) 2006-02-09
KR20080044360A (ko) 2008-05-20
IL180675A0 (en) 2007-06-03
WO2006013427A2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
Tan et al. LNK promotes granulosa cell apoptosis in PCOS via negatively regulating insulin-stimulated AKT-FOXO3 pathway
Rossi et al. Hepatic G i signaling regulates whole-body glucose homeostasis
JP2008501776A (ja) 肥満に関連し、かつメタボリックシンドロームに関連する状態の治療としてのホスホジエステラーゼ１０の阻害
JP2014169295A (ja) マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法
EP1379269B1 (en) Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease
US20120208843A1 (en) Method of Using GPR35 to Identify Metabolic-Stabilizing Compounds
Li et al. Prostanoid EP4 agonist L-902,688 activates PPARγ and attenuates pulmonary arterial hypertension
KR20220011652A (ko) 브루톤 타이로신 키나제 저해제를 사용하여 쇼그렌 증후군을 치료하는 방법
TW200539867A (en) Human g protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders
US20090196823A1 (en) Chemokine antagonists as treatment for obesity-related and metabolic syndrome-related conditions
Ignar et al. Regulation of ingestive behaviors in the rat by GSK1521498, a novel μ-opioid receptor-selective inverse agonist
US20040127395A1 (en) Use of histamine H4 receptor modulators for the treatment of allergy and asthma
JP5153114B2 (ja) 新規のアルツハイマー病検出方法
JP2009051847A (ja) 代謝関連障害を処置するためのｇｐｒ４３およびその調節因子
EP1570860A1 (en) Antagonist and agonist binding to strong binding site of chemokine receptor
KR20070032034A (ko) Ｃｃｒ2 매개 질병 또는 장애의 치료방법
HK1105532A (en) Treatment of ccr2 mediated diseases or disorders
JP2006510590A (ja) アレルギー及び喘息の処置のためのヒスタミンｈ４受容体モジュレーターの使用
TW200539864A (en) Oxydecahydronaphthalene modulators of HM74
WO2006111103A1 (en) Functions and uses of gpr39 gene in mammalian central nervous system
US20250213647A1 (en) Chemokine receptors and alpha1 adrenergic receptors/vasopressin receptors 1a heteromers as drug targets for disease
US20050014742A1 (en) Use of inhibitors of the y2 receptor of neuropeptide y in the treatment of alcoholism
EP1705256A1 (en) Methods for the treatment of insulin resistance and disease states characterized by insulin resistance
JP4044842B2 (ja) 肥満を処置し得る薬剤のスクリーニング法
Connelly et al. The SGLT2i Dapagliflozin Reduces RV Hypertrophy Independent of Changes in RV Pressure Induced by Pulmonary Artery Banding

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080630

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090127